TO THE VISITOR:
About > Immune Complexes > product of antibody binding to antigen.
Designer antibody therapy and antibody design for best capture of analytes in the diagnostic laboratory set the stage for antigen-antibody complexes as illimited scenarios of applications. Immune complexes. Anti-SARS-CoV-2 antibodies bound to the virus might result in two scenarios: (i) neutralisation of the virus (ii) opsonisation of the virus – the first downturning the infectious attack rate, the second enhancing it. In a new vaccine (we write 2021/august), the receptor binding domain (RBD) is tethered above a synthetic nanoparticle; the RBD, more exposed, incites anti-SARS-CoV-2 antibody production more efficiently.
Interaction of Immune Complexes with cells and complement taps into the metabolome and effector systems relevant to human pathology, including, at best, the NLRP3 inflammasome system. Immune Complexes and their receptor lab analytics, including complement system piled up into big data warehouses need to be turned into smart data for the patients – a challenge for primary caretakers cross-examined with this website, immune-complex.ch. In 2019, the four V’s make immune complexes even more thrilling: volume (molecular size), velocity (speed of complex formation between antibody and antigen), variety of information (results from lab tests detecting immune complexes) and value (what does this mean for the patient). Neutralizing monoclonal antibodies might protect from SARS-CoV-2-induced lung infection and inflammation (10.1016/j.cell.2020.06.011), to form immune complexes with the virus as the antigen. Glycation extent of immunoglobulins and whether they are also classified as AGE (advanced glycation end products) in senescence is currently scrutinized.
Fc fragments undergoing sialylation and fucosylation to different extents do change functional performance of the IgG in immune defense.